Clinical Laserthermia Systems (CLS) Q2 2026 earnings summary

Executive summary

• Sales of Prism products rebounded in Q2 2026 after strategic alignment with the neurosurgery partner, resulting in the largest purchase order in company history (SEK 23 million).

• ClearPoint Prism System installations and procedures grew in the U.S., reflecting clinical and commercial momentum.

• Extended research collaboration with the U.S. National Cancer Institute through 2029 to evaluate Tranberg Thermal Therapy System.

• Strategic partnership agreement runs through 2030, supporting long-term growth in minimally invasive neurosurgery.

Financial highlights

• Q2 2026 net sales: SEK 7.65 million, up 485% sequentially from Q1 2026, but below Q2 2025 (SEK 9.36 million).

• Operating loss for Q2 2026: SEK -13.6 million (Q2 2025: SEK -2.9 million); H1 2026: SEK -23.2 million (H1 2025: SEK -10.8 million).

• Net loss for Q2 2026: SEK -12.1 million (Q2 2025: SEK -6.3 million); H1 2026: SEK -19.5 million (H1 2025: SEK -21.6 million).

• Gross margin stable at 62% in Q2 and YTD.

• Cash and cash equivalents at end of Q2 2026: SEK 3.87 million (Q2 2025: SEK 16.2 million).

Outlook and guidance

• Expects strong double-digit revenue growth for full-year 2026 versus 2025, with performance weighted to H2.

• Revenue growth dependent on system placements and LITT procedure ramp-up; variability expected between quarters.

• Additional capital required to reach positive cash flow by Q1 2028; financing preparations underway.